by Reacta Healthcare | Nov 4, 2024 | Business News, Investor News
Praetura Ventures leads £2.9m investment in food allergy diagnostic firm Posted on July 14, 2021 Praetura Ventures, the Manchester-based VC firm, has led a £2.9m funding round to support a business that is on course to transform the food allergy diagnostics market....
by Reacta Healthcare | Nov 4, 2024 | Business News, Milestones
UK Food Allergy Diagnostic company, Reacta Biotech, achieves MHRA GMP licence Posted on June 16, 2021 Pursuant to a capital raise in 2020, Reacta has achieved its goal of securing an MHRA site license This license opens up significant opportunities for the companies...
by Reacta Healthcare | Nov 4, 2024 | Business News, Milestones
Reacta Biotech making progress on peanut diagnostic product Posted on May 19, 2020 Deeside-based Reacta Biotech is on course to secure a market authorisation for its peanut diagnostic product within the next two years as global activity to treat peanut allergies...
by Reacta Healthcare | Nov 4, 2024 | Business News, Investor News
Reacta Healthcare Awarded Major Biomedical Catalyst Grant to develop Paediatric Food allergy diagnostics Posted on April 27, 2022 The £1 million grant will support the development of the first Oral Food Challenges (OFCs) for paediatric patients to diagnose...
by Reacta Healthcare | Nov 4, 2024 | Business News, Investor News
UK food allergy diagnostic company, Reacta Biotech raises £1.25m to continue expansion plans Posted on April 21, 2020 Reacta Biotech raises £1.25m to secure MHRA site license Once achieved, the license will enable significantly expanded production of its Oral Food...
